weight loss drug prescriptions semaglutide tirzepatide q3 2024 data vs Tirzepatide: Real Results Compared [2026] WHO adds GLP-1RAs to essential
Description
(3) Zepbound: approved December 2024 for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity making tirzepatide the first medication approved specifically for OSA
![weight loss drug prescriptions semaglutide tirzepatide q3 2024 data vs Tirzepatide: Real Results Compared [2026] WHO adds GLP-1RAs to essential](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/09/GettyImages-2162809200.jpg)
Not for office use
![weight loss drug prescriptions semaglutide tirzepatide q3 2024 data vs Tirzepatide: Real Results Compared [2026] WHO adds GLP-1RAs to essential](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/shutterstock_2412387783.jpg)
But it does need proper treatment
Both medications were initially developed to treat type 2 diabetes, but clinical results showing dramatic weight reductions sparked their evolution into tools for obesity management
![weight loss drug prescriptions semaglutide tirzepatide q3 2024 data vs Tirzepatide: Real Results Compared [2026] WHO adds GLP-1RAs to essential](https://www.thebrighterside.news/uploads/2026/06/Screenshot-2026-06-16-130538.png?format=auto&optimize=high&width=1440)
The FDA has found fake compounded tirzepatide in the US market with pharmacies on the label that arent even real
![weight loss drug prescriptions semaglutide tirzepatide q3 2024 data vs Tirzepatide: Real Results Compared [2026] WHO adds GLP-1RAs to essential](https://media.nowpatient.com/wp-content/uploads/2025/05/UpcomingWLMeds.png)